Tag
Obicetrapib significantly lowers lipoprotein(a), LDL cholesterol, and apolipoprotein B in high cardiovascular risk patients, offering a promising addition to lipid-lowering therapies, especially for patients with mild to moderate Lp(a) elev
Obicetrapib, a CETP inhibitor, lowers Alzheimer’s biomarkers like p-tau217 in ASCVD patients, especially ApoE4 carriers, suggesting a potential preventive strategy for high-risk individuals.
Obicetrapib significantly reduces LDL cholesterol by nearly 30% in high-risk cardiovascular patients on maximal lipid therapy, with a safety profile comparable to placebo, representing a potential novel agent in managing familial hyperchole
Obicetrapib, a CETP inhibitor, significantly slowed Alzheimer’s disease biomarker progression over 12 months and improved p-tau217 levels in APOE4 carriers while also benefiting lipid profiles in cardiovascular disease patients.
